AI Is Transforming ALS Research and Care

AI sunrise | ALS Worldwide

AI is transforming ALS research and care by accelerating drug discovery, improving diagnostic accuracy and restoring communication for patients through brain-computer interfaces. Projects include:

  1. AI-Driven Communication & BCI Trials 
  • Cognixion (ONE Axon-R): A clinical trial (NCT06810219) launched in early 2025 in the US, testing a wearable headset that combines augmented reality (AR) and BCI with a generative AI application. It is designed to help patients with late-stage ALS communicate by interpreting brain signals, aiming for near-conversational speed.
  • BrainGate2 (Implants): Researchers at Massachusetts General Hospital are using AI to decode neural activity in patients with locked-in ALS, translating brain signals into text or speech in real-time. 
  1. AI in Trial Design and “Digital Twins”
  • ProJenX (PRO-101 Trial): This Phase 1 trial for the drug prosetin uses AI-generated “digital twins” developed by Unlearn. These digital twins act as virtual placebos to enhance evaluation, allowing for a more efficient, data-driven assessment of treatment efficacy.
  • VectorY Therapeutics (PIONEER-ALS): Similar to ProJenX, VectorY is using Unlearn’s AI digital twins in their Phase 1/2 study of a vectorized antibody therapy.
  • NeuroSense Therapeutics (Phase III Trial): Using Machine Learning (ML) technology from PhaseV to analyze data from their Phase III ALS trial to detect biomarkers. 
  1. AI-Discovered Drugs in Trials
  • 4B Technologies (FB1006): An AI-discovered drug for ALS, developed using Insilico Medicine’s AI target identification engine (PandaOmics), finished enrollment in an investigator-initiated trial in early 2024. AI was used for target identification, patient enrollment, and efficacy assessment.
  • Verge Genomics (VRG50635): Verge uses its AI-enabled “CONVERGE” platform to identify new targets and drugs. Their compound, VRG50635, a small-molecule PIKfyve inhibitor, is in Phase 1b trials. 
  1. AI for Diagnosis and Monitoring
  • Mayo Clinic (F-Wave Analysis): Researchers have developed an AI model that analyzes nerve conduction F-wave responses to detect ALS earlier and predict patient survival.
  • Michigan Medicine (Blood Biomarkers): Researchers are using machine learning to identify ALS from blood samples through RNA sequencing, aiding in earlier diagnosis. 
  1. Research Initiatives
  • Answer ALS & LADDIA: A massive collaboration using AI to analyze the largest ALS data repository (Answer ALS) to discover new therapeutic targets, involving partners like GATC Health.
  • ALS Network/TrialX: An AI-based Clinical Trial Finder was launched to help patients identify relevant trials based on their specific, complex, and sometimes non-standardized health data. 

 

Share this news